Bayer AG PK (BAYRY)

OTC Markets
Currency in USD
5.60
+0.17(+3.13%)
Closed
BAYRY Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
Day's Range
5.545.65
52 wk Range
4.798.97
Key Statistics
Edit
Prev. Close
5.43
Open
5.55
Day's Range
5.54-5.65
52 wk Range
4.79-8.97
Volume
1.62M
Average Volume (3m)
1.87M
1-Year Change
-37.78%
Book Value / Share
34.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BAYRY Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
7.59
Upside
+35.54%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period
Show more

Bayer AG PK Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.

Employees
94245

Compare BAYRY to Peers and Sector

Metrics to compare
BAYRY
Peers
Sector
Relationship
P/E Ratio
−23.8x16.0x−0.6x
PEG Ratio
−0.320.030.00
Price/Book
0.7x2.3x2.6x
Price / LTM Sales
0.4x1.9x3.1x
Upside (Analyst Target)
17.3%40.4%50.2%
Fair Value Upside
Unlock10.0%7.5%Unlock

Analyst Ratings

1 Buy
2 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.59
(+35.54% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.896
Dividend Yield
0.39%
Industry Median 1.73%
Annualised payout
0.0217
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Nov 12, 2024
EPS / Forecast
0.0637 / 0.0863
Revenue / Forecast
10.58B / 11.25B
EPS Revisions
Last 90 days

FAQ

What Is the Bayer AG PK (BAYRY) Stock Price Today?

The Bayer AG PK stock price today is 5.60

What Stock Exchange Does Bayer AG PK Trade On?

Bayer AG PK is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Bayer AG PK?

The stock symbol for Bayer AG PK is "BAYRY."

Does Bayer AG PK Pay Dividends? What’s The Current Dividend Yield?

The Bayer AG PK dividend yield is 0.39%.

What Is the Bayer AG PK Market Cap?

As of today, Bayer AG PK market cap is 21.94B.

What is Bayer AG PK Earnings Per Share?

The Bayer AG PK EPS is -0.896.

What Is the Next Bayer AG PK Earnings Date?

Bayer AG PK will release its next earnings report on 04 Mar 2025.

From a Technical Analysis Perspective, Is BAYRY a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.